AU2018366047B2 - Compositions and methods for the treatment of skin lesions - Google Patents

Compositions and methods for the treatment of skin lesions Download PDF

Info

Publication number
AU2018366047B2
AU2018366047B2 AU2018366047A AU2018366047A AU2018366047B2 AU 2018366047 B2 AU2018366047 B2 AU 2018366047B2 AU 2018366047 A AU2018366047 A AU 2018366047A AU 2018366047 A AU2018366047 A AU 2018366047A AU 2018366047 B2 AU2018366047 B2 AU 2018366047B2
Authority
AU
Australia
Prior art keywords
treatment
lesion
patient
scc
cell carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018366047A
Other languages
English (en)
Other versions
AU2018366047A1 (en
Inventor
David Glazer Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glazer Scott David
Original Assignee
Glazer Scott David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glazer Scott David filed Critical Glazer Scott David
Publication of AU2018366047A1 publication Critical patent/AU2018366047A1/en
Application granted granted Critical
Publication of AU2018366047B2 publication Critical patent/AU2018366047B2/en
Priority to AU2024201396A priority Critical patent/AU2024201396A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018366047A 2017-11-09 2018-11-07 Compositions and methods for the treatment of skin lesions Active AU2018366047B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201396A AU2024201396A1 (en) 2017-11-09 2024-03-01 Compositions and methods for the treatment of skin lesions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583979P 2017-11-09 2017-11-09
US62/583,979 2017-11-09
PCT/US2018/059671 WO2019094500A1 (en) 2017-11-09 2018-11-07 Compositions and methods for the treatment of skin lesions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201396A Division AU2024201396A1 (en) 2017-11-09 2024-03-01 Compositions and methods for the treatment of skin lesions

Publications (2)

Publication Number Publication Date
AU2018366047A1 AU2018366047A1 (en) 2020-04-23
AU2018366047B2 true AU2018366047B2 (en) 2023-12-07

Family

ID=64664383

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018366047A Active AU2018366047B2 (en) 2017-11-09 2018-11-07 Compositions and methods for the treatment of skin lesions
AU2024201396A Pending AU2024201396A1 (en) 2017-11-09 2024-03-01 Compositions and methods for the treatment of skin lesions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201396A Pending AU2024201396A1 (en) 2017-11-09 2024-03-01 Compositions and methods for the treatment of skin lesions

Country Status (8)

Country Link
US (1) US10849913B2 (https=)
EP (1) EP3675820A1 (https=)
JP (1) JP7387617B2 (https=)
KR (1) KR20200086326A (https=)
CN (1) CN112243371A (https=)
AU (2) AU2018366047B2 (https=)
CA (1) CA3079256A1 (https=)
WO (1) WO2019094500A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019208322A1 (en) * 2018-01-18 2020-07-23 Taro Pharmaceutical Industries Ltd. Topical capecitabine for the treatment of hyperproliferative skin conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040638A2 (en) * 2014-09-10 2016-03-17 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANILENKO MICHAEL ET AL: "Enhancement by other compounds of the anti-cancer activity of vitamin D3 and its analogs", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 298, no. 2, 2004, p33 -358, DOI: 10.1016/J.YEXCR.2004.04.029 *
HORN Y ET AL: "Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis.", JOURNAL OF SURGICAL ONCOLOGY JUL 1989, vol. 41, no. 3, July 1989 (1989-07-01), p177 182 *
POMMERGAARD ET AL, "Topical combination of diclofenac, calcipotriol, and DFMO has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice", J. OF CHEMOTHERAPY, v 26, n 2, 2014, p 105-110, *
RIVERS, J.K.: "Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel", BR J DERMATOL., vol. 146, no. 1, January 2002 (2002-01-01), pages 94 - 100, XP002788449 *

Also Published As

Publication number Publication date
CA3079256A1 (en) 2019-05-16
JP7387617B2 (ja) 2023-11-28
WO2019094500A1 (en) 2019-05-16
AU2018366047A1 (en) 2020-04-23
US20190134063A1 (en) 2019-05-09
WO2019094500A9 (en) 2019-11-28
US10849913B2 (en) 2020-12-01
CN112243371A (zh) 2021-01-19
AU2024201396A1 (en) 2024-03-21
EP3675820A1 (en) 2020-07-08
KR20200086326A (ko) 2020-07-16
JP2021502420A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
Patel et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial
Dahl et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea
US6524623B1 (en) Therapeutic compositions and methods of use thereof
JP5620443B2 (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
KR20200055067A (ko) 성인의 초점성 뇌전증의 치료를 위한 합성 경피성 칸나비디올
ÖzDEMIR et al. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis
CN105792829A (zh) 使用伊维菌素治疗丘疹脓疱性红斑痤疮
CA2474343A1 (en) Nsaid-containing topical formulations that demonstrate chemopreventive activity
Torras et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
US20120109042A1 (en) Methods of Treating Diseased Tissue
AU2024201396A1 (en) Compositions and methods for the treatment of skin lesions
US20070141182A1 (en) Combination of multiple nonteroidal antiinflammatory drugs and muscle relaxants for local treatment of musculoskeletal pain
Patel et al. Non-psoriatic uses of calcipotriol: a concise updated review
WO2017125523A1 (en) Treatment of hand eczema
Kaminester et al. A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis
CZ112496A3 (en) Application of ibuprofen and flurbiprofen as agents relieving itching and pharmaceutical preparations for such application
US20240165057A1 (en) Compositions and Methods of Achieving Pain Relief
Binnick Pityriasis rubra pilaris responding to aminonicotinamide
HK40038965A (en) Compositions and methods for the treatment of skin lesions
Sharma et al. Efficacy of Azithromycin pulse therapy in acne vulgaris treatment: A hospital based study
Nast et al. Treatment of psoriasis
US9669045B2 (en) Treatments for actinic keratoses
US9789078B2 (en) Method of topically treating actinic keratosis with ingenol mebutate cycle therapy
WO2019072353A1 (en) TOPICAL PHARMACEUTICAL PREPARATION OF BETAMETHASONE, CALCIPOTRIOL AND ROSE OIL FOR THE TREATMENT OF PSORIASIS
Dirschka et al. Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)